The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...